Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2022 |
| Outros Autores: | , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
| Texto Completo: | https://www.arca.fiocruz.br/handle/icict/55138 |
Resumo: | programa “Fazer o bem faz bem”. Conselho Nacional de Pesquisa (CNPq). Fundação de Amparo à Pesquisa do Estado da Bahia (FAPESB). Programa de Apoio a Núcleos de Excelência. Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ. Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Capes). Wellcome Trust. |
| id |
CRUZ_2737be5e830ad6f8bde75a38feb3c067 |
|---|---|
| oai_identifier_str |
oai:www.arca.fiocruz.br:icict/55138 |
| network_acronym_str |
CRUZ |
| network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| repository_id_str |
2135 |
| spelling |
Silva, Thiago CerqueiraOliveira, Vinicius de AraujoPaixão, Enny SBertoldo Júnior, JuracyPenna, Gerson OWerneck, Guilherme LPearce, NeilBarreto, Maurício LBoaventura, Viviane SBarral Netto, Manoel2022-10-14T13:33:04Z2022-10-14T13:33:04Z2022SILVA, Thiago Cerqueira et al. Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil. Nature Communications, v. 13, n. 4154, p. 1-6, 2022.2041-1723https://www.arca.fiocruz.br/handle/icict/5513810.1038/s41467-022-31839-7programa “Fazer o bem faz bem”. Conselho Nacional de Pesquisa (CNPq). Fundação de Amparo à Pesquisa do Estado da Bahia (FAPESB). Programa de Apoio a Núcleos de Excelência. Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ. Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Capes). Wellcome Trust.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. LIB e LEITV Laboratórios. Salvador, BA, Brasil / Universidade Federal da Bahia. Salvador, Bahia, Brasil.Universidade Federal da Bahia. Salvador, Bahia, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Centro de Integração de Dados e Conhecimento para a Saúde. Salvador, BA, Brasil.London School of Hygiene and Tropical Medicine. London WC1E 7HT, UK.Universidade Federal da Bahia. Salvador, Bahia, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Centro de Integração de Dados e Conhecimento para a Saúde. Salvador, BA, Brasil.Universidade de Brasília. Fundação Oswaldo Cruz. Escola Fiocruz de Governo, Núcleo de Medicina Tropical. Brasília, DF, Brasil.Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brasil / Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil.London School of Hygiene and Tropical Medicine. London WC1E 7HT, UK.Universidade Federal da Bahia. Salvador, Bahia, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Centro de Integração de Dados e Conhecimento para a Saúde. Salvador, BA, Brasil.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. LIB e LEITV Laboratórios. Salvador, BA, Brasil / Universidade Federal da Bahia. Salvador, Bahia, Brasil.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. LIB e LEITV Laboratórios. Salvador, BA, Brasil / Universidade Federal da Bahia. Salvador, Bahia, Brasil.To date, no information has been published on the effectiveness of inactivated whole-virus COVID-19 vaccines plus heterologous booster against symptomatic infection and severe outcomes (hospitalization or death) during the dominance of the SARS-CoV-2 Omicron variant period. We evaluated the vaccine effectiveness (VE) of CoronaVac plus BNT162b2 booster during the period of dominance of the Omicron variant in Brazil (January to April 2022). Using a test-negative design, we analysed data for 2,471,576 individuals tested during the Omicron variant’s dominant period using a nationally linked database from Brazil. Compared to unvaccinated, vaccinees maintained protection against severe outcomes, with an estimated VE of 84.1% (95% CI:83.2–84.9) at more than 120 days after BNT162b2 booster. Furthermore, while we detected a high level of protection against severe outcomes for individuals up to 79 years old, waning was observed for individuals aged ≥80 years, with VE decreasing from 81.3% (95% CI:77.9–84.2) at 31–60 days to 72.9% (95% CI:70.6–75.1) at 120 days or more after the booster dose. However, no significant protection against symptomatic infection was observed at this time period. In conclusion, except for individuals aged ≥80 years, CoronaVac plus a BNT162b2 booster dose offered high and durable protection against severe outcomes due to Omicron.engNature ResearchBNT162 VaccineProteçãoCoronaVacHeterólogoBNT162b2OmicronBrasilProtectionCoronaVacHeterologousBNT162b2OmicronBrazilVacina BNT162Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazilinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/55138/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALSilva, Thiago C . - Duration of protection of CoronaVac.pdfSilva, Thiago C . - Duration of protection of CoronaVac.pdfapplication/pdf640738https://www.arca.fiocruz.br/bitstream/icict/55138/2/Silva%2c%20Thiago%20C%20.%20%20-%20Duration%20of%20protection%20of%20CoronaVac.pdf88c3f3bc3693253e8524b5cf8e4410c5MD52icict/551382023-03-15 14:32:51.95oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-03-15T17:32:51Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
| dc.title.en_US.fl_str_mv |
Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil |
| title |
Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil |
| spellingShingle |
Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil Silva, Thiago Cerqueira BNT162 Vaccine Proteção CoronaVac Heterólogo BNT162b2 Omicron Brasil Protection CoronaVac Heterologous BNT162b2 Omicron Brazil Vacina BNT162 |
| title_short |
Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil |
| title_full |
Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil |
| title_fullStr |
Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil |
| title_full_unstemmed |
Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil |
| title_sort |
Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil |
| author |
Silva, Thiago Cerqueira |
| author_facet |
Silva, Thiago Cerqueira Oliveira, Vinicius de Araujo Paixão, Enny S Bertoldo Júnior, Juracy Penna, Gerson O Werneck, Guilherme L Pearce, Neil Barreto, Maurício L Boaventura, Viviane S Barral Netto, Manoel |
| author_role |
author |
| author2 |
Oliveira, Vinicius de Araujo Paixão, Enny S Bertoldo Júnior, Juracy Penna, Gerson O Werneck, Guilherme L Pearce, Neil Barreto, Maurício L Boaventura, Viviane S Barral Netto, Manoel |
| author2_role |
author author author author author author author author author |
| dc.contributor.author.fl_str_mv |
Silva, Thiago Cerqueira Oliveira, Vinicius de Araujo Paixão, Enny S Bertoldo Júnior, Juracy Penna, Gerson O Werneck, Guilherme L Pearce, Neil Barreto, Maurício L Boaventura, Viviane S Barral Netto, Manoel |
| dc.subject.mesh.en_US.fl_str_mv |
BNT162 Vaccine |
| topic |
BNT162 Vaccine Proteção CoronaVac Heterólogo BNT162b2 Omicron Brasil Protection CoronaVac Heterologous BNT162b2 Omicron Brazil Vacina BNT162 |
| dc.subject.other.en_US.fl_str_mv |
Proteção CoronaVac Heterólogo BNT162b2 Omicron Brasil |
| dc.subject.en.en_US.fl_str_mv |
Protection CoronaVac Heterologous BNT162b2 Omicron Brazil |
| dc.subject.decs.en_US.fl_str_mv |
Vacina BNT162 |
| description |
programa “Fazer o bem faz bem”. Conselho Nacional de Pesquisa (CNPq). Fundação de Amparo à Pesquisa do Estado da Bahia (FAPESB). Programa de Apoio a Núcleos de Excelência. Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ. Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Capes). Wellcome Trust. |
| publishDate |
2022 |
| dc.date.accessioned.fl_str_mv |
2022-10-14T13:33:04Z |
| dc.date.available.fl_str_mv |
2022-10-14T13:33:04Z |
| dc.date.issued.fl_str_mv |
2022 |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.citation.fl_str_mv |
SILVA, Thiago Cerqueira et al. Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil. Nature Communications, v. 13, n. 4154, p. 1-6, 2022. |
| dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/55138 |
| dc.identifier.issn.en_US.fl_str_mv |
2041-1723 |
| dc.identifier.doi.none.fl_str_mv |
10.1038/s41467-022-31839-7 |
| identifier_str_mv |
SILVA, Thiago Cerqueira et al. Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil. Nature Communications, v. 13, n. 4154, p. 1-6, 2022. 2041-1723 10.1038/s41467-022-31839-7 |
| url |
https://www.arca.fiocruz.br/handle/icict/55138 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
Nature Research |
| publisher.none.fl_str_mv |
Nature Research |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
| instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
| instacron_str |
FIOCRUZ |
| institution |
FIOCRUZ |
| reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| collection |
Repositório Institucional da FIOCRUZ (ARCA) |
| bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/55138/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/55138/2/Silva%2c%20Thiago%20C%20.%20%20-%20Duration%20of%20protection%20of%20CoronaVac.pdf |
| bitstream.checksum.fl_str_mv |
5a560609d32a3863062d77ff32785d58 88c3f3bc3693253e8524b5cf8e4410c5 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
| repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
| _version_ |
1813009233047715840 |